RecruitingPhase 2NCT05926700

Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

Studying Soft tissue sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Principal Investigator
Ying Dong
Second Affiliated Hospital, School of Medicine, Zhejiang University
Intervention
Candonilimab(drug)
Enrollment
27 enrolled
Eligibility
18-70 years · All sexes
Timeline
2024 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05926700 on ClinicalTrials.gov

Other trials for Soft tissue sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Soft tissue sarcoma →

← Back to all trials